Glioblastoma multiforme recurrent

Lederman G, Arbit E, Odaimi M, Wertheim S, Lombardi E. Recurrent glioblastoma multiforme potential benefits using fractionated stereotactic radiotherapy and concurrent taxol. Stereotact Fund Neurosurg 1997 69(1—4 Pt 2) 162-174. 

Lederman G, Arbit E, Odaimi M, Lombardi E, Wrzolek M, Wronski M. Fractionated stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma multiforme a preliminary report. Int J Radiat Oncol Biol Phys 1998 40(3) 661-666. 

Gliadel is a biodegradable polyanhydride implant composed of poly[bis(p-carboxyphenoxy) propane sebacic acid] in a 20 80 monomer ratio, for the delivery of carmustine. The implant is indicated in the treatment of recurrent glioblastoma multiforme (GBM) which is the most common and fatal type of brain cancer. 

Buie LW, Valgus J (2008) Bevacizumab a treatment option for recurrent glioblastoma multiforme. Ann Pharmacother 42 1486-1490... 

Gene Therapy for the Treatment of Recurrent Glioblastoma Multiforme with In Vivo Tumor Transduction with the Herpes Simplex-Thymidine Kinase Gene/Ganciclovir System... 

GBM glioblastoma multiforme HG high grade glioma cr complete response recur recurrent tumors. 

Two patients with primary glioblastoma multiforme WHO grade 4 were treated in addition with 60 Gy of XRT and died 9 and 15 months afterwards. The patients with recurrent GBMs (n = 14) demonstrated a median time to progression of 4 months and a median survival time of 7 months, four patients are living with a follow up of up to 24 months. The patients with metastasis demonstrated complete tumor control in two cases for up to 28 months, 2 were progressing 6 months after treatment and were lost to follow up. One skull base tumor demonstrated a complete response with a follow up of 24 months, the other relapsed within 7 months. 

Ren H, et al. (2003). Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene—a phase I/II clinical protocol. J. Neurooncol. 64 147-154. 

Barker EG, Chang SM, Gutin PH, Malek MK, McDermott MW, Prados MD, Wilson CB. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998 42 709-720. 

Vredenburgh JJ et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Journal of Clinical Oncology 2007 25 4722-4729. 

Van den Bent MJ, Braudes A, Rampling R, Kouwenhoven M, Kros JM, Carpentier A et al. Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM) EORTC 26034. 2007 ASCO Annual Meeting J Clin Oncol 2001, 18S. 

Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005 23 357-361. 

Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme a North Central Cancer Treatment Group Study. J Clin Oncol 2005 23 5294-5304. 

Schiff D, Purow B. Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme. Nat Clin Pract Oncol 200 , 5 186-187. 

Blancher A, Roubinet F, Grancher AS, Tremoulet M, Bonate A, Delisle MB et al. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells. Eur Cytokine Netw 1993 4 331-341. 

Merchant RE, Grant AJ, Merchant LH, Young HF. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2. Cancer 1988 62 665-671. 

Mittelman, A Chim, H,G Pucdo, C., Coombe, N., Lansen, T and Ahmed, T, (1999) Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319), Invest. Neiv Drugs, 17,179-182. 

---